As expected, GLP-1R agonism resulted in a reduced intake of both control liquid and ethanol diets, and a corresponding reduction of body weight in both the control and ethanol groups (Supplementary Fig
doi:10.1056/NEJMoa2204601 Haddad F, Dokmak G, Bader M, et al
Patients included in PIONEER 5 and PIONEER 6 were living with moderate renal impairment (eGFR 30 to 59 mL/min/1.73 m 2 ), and cardiovascular disease, respectively
Tirzepatide is a dual agonist that activates the GLP-1 and GIP receptors
See our privacy policy
The agency has authorized the use of Wegovy for adults with a BMI of 30 or more, or those with a BMI of 27 plus at least one weight-related condition, such as high blood pressure, high cholesterol, or type-two diabetes